PB 148 of 2024
National Health (April 2025 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2024
National Health Act 1953
I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following determination.
Dated 19 December 2024
EDEN SIMON
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Health Resourcing Group
Department of Health and Aged Care
1 Name
(1) This instrument is the National Health (April 2025 Price Reductions) (Exercise of Ministerial discretion) Determination (No.1) 2024.
(2) This instrument may also be cited as PB 148 of 2024.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 January 2025 |
|
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Definition
Note: A number of expressions used in this instrument are defined in Part VII the Act.
In this instrument:
Act means the National Health Act 1953.
reduction day in this instrument refers to 1 April 2025.
4 Authority
This instrument is made under subsection 99ACF(3) of the Act.
5 Brand of pharmaceutical item not subject to a price reduction
I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is not reduced under a provision mentioned in item 2A or item 3A or item 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day.
6 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply
I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of a brand of pharmaceutical item specified in column 2 of an item in the table in Schedule 2 is reduced under a provision mentioned in items 2A or 4A of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the reduction day by the percentage specified in column 3 of the table item.
Schedule 1 — Brands of pharmaceutical items with approved ex-manufacturer price not reduced
Column 1 | Column 2 | |||
Item | Brand of Pharmaceutical Item | |||
| Drug | Form | Manner of administration | Brand(s) |
1 | Arginine with carbohydrate | Sachets of oral powder 4 g containing 500 mg arginine, 30 (Arginine 500) | Oral | Arginine 500 |
2 | Arginine with carbohydrate | Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000) | Oral | Arginine 2000 |
3 | Arginine with carbohydrate | Sachets of oral powder 7.6 g containing 5 g arginine, 30 (Arginine 5000) | Oral
| Arginine 5000 |
4 | Encorafenib | Capsule 50 mg | Oral
| Braftovi |
5 | Essential amino acids formula | Oral powder 200 g (Essential Amino Acid Mix) | Oral
| Essential Amino Acid Mix |
6 | High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral liquid 200 mL, 32 (KetoCal 4:1 LQ) | Oral
| KetoCal 4:1 LQ |
7 | High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral semi-solid 100 g, 36 (K.Yo) | Oral
| K.Yo |
8 | Mupirocin | Nasal ointment 20 mg (as calcium) per g, 5 g | Nasal | Mupirocin Nasal (Medsurge) |
9 | Vitamins, minerals and trace elements with carbohydrate | Oral powder 200 g (Paediatric Seravit) | Oral | Paediatric Seravit |
10 | Vitamins, minerals and trace elements with carbohydrate | Sachets containing oral powder 6 g, 30 (FruitiVits) | Oral | FruitiVits |
Schedule 2 — Brands of pharmaceutical items with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply
Column 1 | Column 2 | Column 3 | |||
Item | Brand of pharmaceutical item | % reduction | |||
| Drug | Form | Manner of administration | Brand |
|
1 | Binimetinib | Tablet 15 mg | Oral | Mektovi | 2.50% |
2 | Encorafenib | Capsule 75 mg | Oral | Braftovi | 2.50% |
3 | High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral powder 300 g (KetoCal 3:1) | Oral | KetoCal 3:1 | 15.75% |
4 | High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate | Oral powder 300 g (KetoCal 4:1) | Oral | KetoCal 4:1 | 11.64% |